Pfizer in investment phase in India as it moves into diabetes and branded generics
This article was originally published in Scrip
Executive Summary
Pfizer India, traditionally known for its dependence on the parent company's innovative product portfolio, is expanding its horizons on the domestic market to propel growth. The Indian arm, which has just moved into the diabetes segment, anticipates strong growth in the branded generics segment, where it is also planning to take the plunge.